(MedPage Today) — NEW ORLEANS — Once-daily orforglipron (Foundayo) improved outcomes in adults with type 2 diabetes and inadequate glycemic control, the international ACHIEVE-5 trial showed.
In patients already taking background insulin glargine…
Source link
Ad Banner
Show Comments (0)
Hide Comments (0)
Subscribe
Login
0 Comments
Oldest
